Conditions: Asymptomatic Multiple Myeloma
Keywords: Asymptomatic Multiple Myeloma Auto-ENK Cell Therapy Natural Killer Cells
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 3
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the safety and in vivo persistence and expansion of autologous and expansion of autologous, ex vivo expanded-natural killer(ENK) cells.

Detailed description:
To determine whether significant in vivo expansion of auto-ENK cells occurs, defined as a \> 4 fold increase in absolute cluster of differentiation 3(CD3)-cluster of differentiation 56 (CD56+) NK cell count/blood 7 days after infusion over the pre-study baseline level and the safety of the ENK cell therapy in research participants with high-risk asymptomatic multiple myeloma (AMM) defined as gene expression profile (GEP) 70 gene score\>-0.26.

Arms:
arm 1: Expanded Natural Killer Cell Infusion

Interventions: intervention 1: ENK Cell Infusion
Intervention descriptions: intervention 1: Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU

Protocol document: